This survey describes patterns of pneumococcal polysaccharide vaccine use, vaccine registration, vaccination recommendations, and reimbursement for vaccination in the United States and 20 other developed countries during the period 1981 through 1996. The United States was the only country to use appreciable amounts of the vaccine throughout the study period. Annual vaccine use was stable from 1982 through 1990 but then increased sharply. In the 20 other countries, very little pneumococcal vaccine was used until the 1990s, when new registrations and/or national recommendations were followed by dramatic increases in vaccine use in Iceland
Pneumococcal infections continue to be an important cause cal vaccination is supported by convincing evidence that vaccination is Ç50% -70% effective in preventing invasive pneuof hospital admission and death in developed countries. Among all occurrences in adults of community-acquired pneumonia mococcal disease in older adults [1, 14, 18] . requiring hospital admission, Streptococcus pneumoniae ranks first among known microbial causes and accounts for Ç30% -See the editorial response by Breiman on pages 1124 -6. 50% of such cases [1] . Invasive pneumococcal disease is common among older adults in the United States [2 -9] . Recent
In spite of broad interest in pneumococcal vaccination, there reports from Denmark [10] , Norway [11] , Sweden (Å . Ö rtqvist, is little information on the extent to which the vaccine has personal communication, August 1997), Israel [12] , and Canactually been used [1, 16] . In contrast, much more is known ada [13] suggest the incidence in other developed countries about the use of influenza vaccine, a vaccine recommended for may be similar. much the same target population. Recent studies covering the In 1977, 14-valent pneumococcal polysaccharide vaccine period from 1980 to 1995 document wide variations in influwas registered in the United States and soon thereafter in Canenza vaccination among developed countries [19, 20] . Moreada and several other countries. In 1983 it was replaced by a over, national recommendations for influenza vaccination and 23-valent preparation containing the capsular polysaccharides policies for vaccination reimbursement also vary among counof S. pneumoniae types known to account for Ç90% of invasive tries, and these factors appear to have had substantial impact pneumococcal disease [1] . Five sets of recommendations on on levels of vaccine use. the use of pneumococcal vaccine have been published in the This report describes patterns of pneumococcal vaccine disUnited States [1, 14] , and a similar number have appeared in tribution in the United States and 20 other developed countries Canada [15, 16] mendations include asplenia and most include a broad range of conditions associated with immunocompromise, including HIV infection. Most countries also include persons with cardioResults pulmonary and renal diseases and diabetes mellitus, but heart disease is not mentioned in France and diabetes mellitus and The United States was the only country that used appreciable amounts of pneumococcal vaccine throughout the study period renal diseases are omitted in Austria.
Vaccination is recommended for all elderly persons in 10 (figure 1). In 1981, 99 doses of vaccine were distributed per 10,000 population, and distribution ranged from 49 to 64 doses countries and for nursing home residents in 6, although only 5 of these countries recommend vaccination for both groups. per 10,000 population per year during the period from 1982 through 1990. Vaccine distribution began to increase in 1991, Italy registered both 14-valent and 23-valent pneumococcal vaccines but has never issued recommendations for their use. In reaching 267 doses per 10,000 population in 1996 (R. A. Strikas, personal communication, June 1997).
Spain, Portugal, and Greece, pneumococcal vaccine is neither registered nor recommended, although in the autonomous reIn contrast with its use in the United States, only small amounts of pneumococcal vaccine were used in Canada, gion of Catalonia in Spain recommendations almost identical to those for the United States were issued in 1993 [27]. France, Australia, and Switzerland during the 1980s, and little if any was distributed in the other 16 countries (figure 1).
Methods for providing reimbursement for pneumococcal vaccination of recommended groups also show substantial variFrom 1990 through 1993, vaccine usage increased slightly in Denmark and the United Kingdom. In Finland, a large clinical ation (table 1) . Ten countries provide public reimbursement through some form of national or social health insurance. In trial caused vaccine distribution to rise to 70 doses per 10,000 population in 1992. Remarkably, Iceland purchased 584 doses countries where the vaccine has not been registered and vaccine use is very low (e.g., Spain), public reimbursement has been per 10,000 population in 1991. In the other countries, vaccine use remained at £5 doses per 10,000 population until 1994, provided for small numbers of patients, usually those with asplenia, who are vaccinated on a compassionate (i.e., namedwhen a substantial increase was noted in the United Kingdom. up through 1996. As a result, vaccination rates among elderly cal disease and heightened concern over the rapid increase in antimicrobial resistance among strains of S. pneumoniae [36] . and high-risk persons were certainly much lower than those in the United States. Consider, for example, the 17 countries of
In the United Kingdom, vaccine use increased after the Joint Committee on Vaccination and Immunisation issued its first Western Europe included in this study. In 1996, the population of persons §65 years of age living in these countries was Ç57 recommendation on pneumococcal vaccine in 1992 [22] . In Belgium, the first set of recommendations in 1993 [23] was million. If it is assumed that all the pneumococcal vaccine distributed in these countries during the 5-year period from followed by registration in 1995 and an immediate increase in vaccine use. Expanded recommendations in Sweden and Nor-1992 through 1996 was given to persons in this age group, and if it is also assumed that none of those who were vaccinated way (asplenia was the only condition previously mentioned), together with registration in Norway, account for the increase died of any cause, then the 2,761,000 doses of vaccine distributed would have been sufficient to vaccinate õ5% of all elderly in vaccination noted in these two countries.
The most dramatic increase in pneumococcal vaccine use persons in Western Europe.
In a few of these countries, however, vaccination increased occurred in Canada in 1996. Since the late 1970s, Canadian recommendations for pneumococcal vaccination have been dramatically, and specific policy decisions appear to be largely responsible for these changes. Iceland's large vaccine purchase similar to those in the United States [15] . In spite of these recommendations, however, very little vaccine was used until in 1991 reflected both the conviction among health authorities that vaccination was useful in preventing invasive pneumococ-1996 [16] . The sudden increase reflected the decision of the / 9c4c$$my03 04-10-98 01:25:25 cidas UC: CID health officials in Ontario to achieve within 3 years a high level and perhaps the United Kingdom, but the same cannot be said for other countries. In Iceland, Sweden, Norway, and Belgium of vaccine coverage among recommended groups, including all the cost of pneumococcal vaccination is still borne privately, persons §65 years of age.
yet the vaccine is being used (table 1) . Even in the United In 1996, the provincial health department purchased almost States, inadequate reimbursement under Medicare provided 500,000 doses of pneumococcal vaccine for free distribution to few if any financial incentive until recently for physicians to physicians and coordinated a public and professional awareness give or patients to receive the vaccine [31] . campaign. In addition, the provincial health insurance system Among the four countries considered to be developed market reimbursed physicians for administering the vaccine. As a reeconomies but not included in this report, Japan is the only sult of this program, the provincial rate for pneumococcal vacone of any size [21] . Data on pneumococcal vaccine use in cine distribution in 1996 was 402 doses per 10,000 population, Japan are unavailable, although very few doses are known to and Ontario accounted for 90.5% of the total amount of vaccine have been distributed and there is neither a national recommendistributed throughout Canada. In the remaining provinces and dation nor public reimbursement for pneumococcal (or influterritories, vaccine distribution was only 25 doses per 10,000 enza [20]) vaccination. Luxembourg, Monaco, and San Marino population, a level comparable to that in France.
are the three remaining countries, and information is available No single explanation accounts for the continued lack of use only for vaccination recommendations in Luxembourg. They of pneumococcal vaccine in the other 20 countries included in were issued in 1992 and are identical to those in neighboring this report. However, the decisions of the vaccine manufacturBelgium, except for an age recommendation at 55 years [37] . ers have played an important role. Between 1977 and 1981, at The failure to use pneumococcal vaccine in developed counleast one of the companies registered and marketed its 14-valent tries over the past 20 years is undeniable. Perhaps no other in seven of these countries (table 1) . Nonetheless, national vaccine that has come to the market over the past 50 years has recommendations soon followed in only three countries, and been so widely ignored by so many countries for so long. in two (France and Norway) they were highly restrictive. BeNonetheless, the increases in vaccine use noted in the United cause very few doses of their 14-valent vaccines had been sold, States and Iceland (1991), the United Kingdom (1994), Sweden the companies made limited efforts to register their 23-valent (1995) , and Norway, Belgium, and Canada (1996) are soon products when they became available in 1983 and did little to likely to be followed by similar changes in many other counpromote them over the next decade. Moreover, in spite of tries. New registrations are expected and will be important: in an increase in the number of vaccine registrations and in the 1996, pneumococcal vaccine was actively marketed (in addimanufacturers' promotional efforts in the mid-1990s, by the tion to being registered) by more than one manufacturer only end of 1996 only the United Kingdom, Sweden, and Belgium in Sweden, Belgium, and the United States, and market compehad registered products from more than one company.
tition may have contributed to the overall level of vaccine use In striking contrast to their use of pneumococcal vaccine, in these three countries. many of these 20 countries have shown substantial increases New vaccination recommendations are also expected soon in influenza vaccination over the past decade [19, 20] . Spain in France and the Netherlands and later in other countries. and Italy are the leaders for influenza vaccination in western Equally important will be a growing awareness that the inciEurope. Most of the doses of influenza vaccine used are purdence of invasive pneumococcal disease is probably similar in chased by regional health departments and given to patients free most developed countries [2 -13] and that for elderly persons in public clinics. It appears that the unwillingness of regional vaccination is both clinically effective [1, 14] and highly costgovernments to purchase pneumococcal vaccine is the main effective [38] in preventing pneumococcal bacteremia alone. reason for its lack of use in these two countries. In France,
The continuing spread of antimicrobial resistance among there is no recommendation for pneumococcal vaccination of S. pneumoniae [39] and the possibility that pneumococcal conall elderly persons [24], nor is public reimbursement provided; jugate vaccines will be used for priming in adults [40] as well this is unlike the policy for influenza vaccination, which is as in children [41] will also contribute to the increased use of recommended for all persons §70 years of age and for which pneumococcal polysaccharide vaccine. This increase may not public reimbursement is provided [19] . Not surprisingly, inflube limited to developed countries. Rapid economic change in enza vaccine use in France is high [19, 20] , whereas pneumodeveloping countries and wider understanding of the imporcoccal vaccine use remains low.
tance of S. pneumoniae as probably the leading cause of death In four other countries (Switzerland, the Netherlands, Ausdue to lower respiratory infections in persons of all ages worldtralia, and Germany), national authorities recommend influenza wide [42] should lead to a dramatic growth in pneumococcal vaccine but not pneumococcal vaccine for persons §65 years vaccination in many countries within the next few years. of age, and appreciable amounts of influenza but not pneumoAddendum coccal vaccine have been used. It is also worth noting that public reimbursement appears to have been an important factor Since this article was submitted for publication, several changes have occurred (in 1997). Australia now recommends in raising the level of pneumococcal vaccine use in Ontario / 9c4c$$my03 04-10-98 01:25:25 cidas UC: CID
